Study on the Interaction Between C3 Gene Polymorphism and Environment in Patients with Type 2 Diabetes Combined with Coronary Artery Disease

References

• Ahmad E, Lim S, Lamptey R., et al. Type 2 diabetes. Lancet. 2022;400(10365):1803–1820. doi:10.1016/S0140-6736(22)01655-5
   PubMed Web of Science ®Google Scholar
• Nazarzadeh M, Bidel Z, Canoy D, et al. Blood pressure lowering and risk of new-onset type 2 diabetes, an individual participant data meta-analysis. Lancet. 2021;398(10313):1803–1810. doi:10.1016/S0140-6736(21)01920-6
   PubMed Web of Science ®Google Scholar
• Shlomai G, Neel B, LeRoith D, et al. Type 2 diabetes mellitus and cancer, the role of pharmacotherapy. J Clin Oncol. 2016;34(35):4261–4269. doi:10.1200/JCO.2016.67.4044
   PubMed Web of Science ®Google Scholar
• Zhou B, Lu Y, Hajifathalian K, et al. Worldwide trends in diabetes since 1980, a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet. 2016;387(10027):1513–1530. doi:10.1016/S0140-6736(16)00618-8
   PubMed Web of Science ®Google Scholar
• Shi FH, Shen L, Pan MM, et al. The successful rapid adjustment of blood glucose in a patient with acute coronary syndrome, renal insufficiency, and diabetes, a case report of management coordinated by clinical pharmacists and clinicians. Front Pharmacol. 2020;11:756. doi:10.3389/fphar.2020.00756
   PubMed Web of Science ®Google Scholar
• Huang ES. Management of diabetes mellitus in older people with comorbidities. BMJ. 2016;353:i2200. doi:10.1136/bmj.i2200
   PubMedGoogle Scholar
• Toi PL, Anothaisintawee T, Chaikledkaew U, et al. Preventive role of diet interventions and dietary factors in Type 2 diabetes mellitus, an umbrella review. Nutrients. 2020;12(9). doi:10.3390/nu12092722
   PubMed Web of Science ®Google Scholar
• Weihrauch M, Handschin C. Pharmacological targeting of exercise adaptations in skeletal muscle, benefits and pitfalls. Biochem Pharmacol. 2018;147:211–220. doi:10.1016/j.bcp.2017.10.006
   PubMed Web of Science ®Google Scholar
• Park S, Rhee SY, Jeong SJ, et al. Features of long-standing Korean Type 2 diabetes mellitus patients with diabetic retinopathy, a study based on standardized clinical data. Diabetes Metab J. 2017;41(5):393–404. doi:10.4093/dmj.2017.41.5.393
   PubMed Web of Science ®Google Scholar
• Zhang S, Wang S, Puhl MD, et al. Global biochemical profiling identifies beta-hydroxypyruvate as a potential mediator of type 2 diabetes in mice and humans. Diabetes. 2015;64(4):1383–1394. doi:10.2337/db14-1188
   PubMed Web of Science ®Google Scholar
• Emerging Risk Factors C, Sarwar N, Gao P, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease, a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375(9733):2215–2222. doi:10.1016/S0140-6736(10)60484-9
   PubMed Web of Science ®Google Scholar
• Chatterjee S, Khunti K, Davies MJ. Type 2 diabetes. Lancet. 2017;389(10085):2239–2251. doi:10.1016/S0140-6736(17)30058-2
   PubMed Web of Science ®Google Scholar
• Honigberg MC, Chang LS, McGuire DK, et al. Use of glucagon-like Peptide-1 receptor agonists in patients with Type 2 diabetes and cardiovascular disease, a review. JAMA Cardiol. 2020;5(10):1182–1190. doi:10.1001/jamacardio.2020.1966
   PubMed Web of Science ®Google Scholar
• Wilcox T, De Block C, Schwartzbard AZ, et al. Diabetic agents, from metformin to SGLT2 inhibitors and GLP1 receptor agonists, JACC focus seminar. J Am Coll Cardiol. 2020;75(16):1956–1974. doi:10.1016/j.jacc.2020.02.056
   PubMed Web of Science ®Google Scholar
• Perreault L, Boardman MK, Pak J. The association between Type 2 diabetes and cardiovascular disease, the ”for your sweetheart” survey. Adv Ther. 2019;36(3):746–755. doi:10.1007/s12325-019-0871-9
   PubMed Web of Science ®Google Scholar
• Siddiqui MB, Arshad T, Patel S, et al. Small dense low-density lipoprotein cholesterol predicts cardiovascular events in liver transplant recipients. Hepatology. 2019;70(1):98–107. doi:10.1002/hep.30518
   PubMed Web of Science ®Google Scholar
• Horejsi B, Ceska R. Apolipoproteins and atherosclerosis. Apolipoprotein E and apolipoprotein(a) as candidate genes of premature development of atherosclerosis. Physiol Res. 2000;49(Suppl 1):S63–9.
   PubMedGoogle Scholar
• Lidani KCF, Bavia L, Ambrosio AR, et al. The complement system, a prey of trypanosoma cruzi. Front Microbiol. 2017;8:607. doi:10.3389/fmicb.2017.00607
   PubMed Web of Science ®Google Scholar
• Merle NS, Church SE, Fremeaux-Bacchi V, et al. Complement system part i - molecular mechanisms of activation and regulation. Front Immunol. 2015;6:262. doi:10.3389/fimmu.2015.00262
   PubMed Web of Science ®Google Scholar
• Haj Ahmad RM A, Al-Domi HA. Complement 3 serum levels as a pro-inflammatory biomarker for insulin resistance in obesity. Diabetes Metab Syndr. 2017;11(Suppl 1):S229–S32. doi:10.1016/j.dsx.2016.12.036
   PubMedGoogle Scholar
• Bratti LOS, Do Carmo IAR, Vilela TF, et al. Complement component 3 (C3) as a biomarker for insulin resistance after bariatric surgery. Clin Biochem. 2017;50(9):529–532. doi:10.1016/j.clinbiochem.2017.02.006
   PubMed Web of Science ®Google Scholar
• Ursini F, Abenavoli L. The emerging role of complement C3 as a biomarker of insulin resistance and cardiometabolic diseases, preclinical and clinical evidence. Rev Recent Clin Trials. 2018;13(1):61–68. doi:10.2174/1574887112666171128134552
   PubMedGoogle Scholar
• Jiang H, Guo M, Dong L, et al. Levels of acylation stimulating protein and the complement component 3 precursor are associated with the occurrence and development of coronary heart disease. Exp Ther Med. 2014;8(6):1861–1866. doi:10.3892/etm.2014.2018
   PubMed Web of Science ®Google Scholar
• van Greevenbroek MM, Jacobs M, van der Kallen CJ, et al. Human plasma complement C3 is independently associated with coronary heart disease, but only in heavy smokers (the CODAM study). Int J Cardiol. 2012;154(2):158–162. doi:10.1016/j.ijcard.2010.09.017
   PubMed Web of Science ®Google Scholar
• Nsaiba MJ, Lapointe M, Mabrouk H, et al. C3 polymorphism influences circulating levels of C3, ASP and lipids in schizophrenic patients. Neurochem Res. 2015;40(5):906–914. doi:10.1007/s11064-015-1543-z
   PubMed Web of Science ®Google Scholar
• Wagner EK, Raychaudhuri S, Villalonga MB, et al. Mapping rare, deleterious mutations in Factor H, Association with early onset, drusen burden, and lower antigenic levels in familial AMD. Sci Rep. 2016;6:31531. doi:10.1038/srep31531
   PubMed Web of Science ®Google Scholar
• Leban N, Jraba K, Chalghoum A, et al. Polymorphism of C3 complement in association with myocardial infarction in a sample of central Tunisia. Diagn Pathol. 2013;8:93. doi:10.1186/1746-1596-8-93
   PubMed Web of Science ®Google Scholar
• American Diabetes A. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;37(Suppl 1):S81–90. doi:10.2337/dc14-S081
   PubMedGoogle Scholar
• Onat A, Can G, Rezvani R, et al. Complement C3 and cleavage products in cardiometabolic risk. Clin Chim Acta. 2011;412(13–14):1171–1179. doi:10.1016/j.cca.2011.03.005
   PubMed Web of Science ®Google Scholar
• Hertle E, van Greevenbroek MM, Stehouwer CD. Complement C3, an emerging risk factor in cardiometabolic disease. Diabetologia. 2012;55(4):881–884. doi:10.1007/s00125-012-2462-z
   PubMed Web of Science ®Google Scholar
• Gudjonsson A, Gudmundsdottir V, Axelsson GT, et al. A genome-wide association study of serum proteins reveals shared loci with common diseases. Nat Commun. 2022;13(1):480. doi:10.1038/s41467-021-27850-z
   PubMed Web of Science ®Google Scholar
• Khan A, Shang N, Petukhova L, et al. Medical records-based genetic studies of the complement system. J Am Soc Nephrol. 2021;32(8):2031–2047. doi:10.1681/ASN.2020091371
   PubMed Web of Science ®Google Scholar
• Engstrom G, Hedblad B, Eriksson KF, et al. Complement C3 is a risk factor for the development of diabetes, a population-based cohort study. Diabetes. 2005;54(2):570–575. doi:10.2337/diabetes.54.2.570
   PubMed Web of Science ®Google Scholar
• Borne Y, Muhammad IF, Lores-Motta L, et al. Complement C3 associates with incidence of diabetes, but no evidence of a causal relationship. J Clin Endocrinol Metab. 2017;102(12):4477–4485. doi:10.1210/jc.2017-00948
   PubMed Web of Science ®Google Scholar
• Sena L, Oliveira-Tore CF, Skare T, et al. C3 gene functional polymorphisms and C3 serum levels in patients with rheumatoid arthritis. Immunol Invest. 2021;50(8):1027–1041. doi:10.1080/08820139.2020.1800726
   PubMed Web of Science ®Google Scholar
• Lu F, Liu S, Hao Q, et al. Association between complement factor C2/C3/CFB/CFH polymorphisms and age-related macular degeneration, a meta-analysis. Genet Test Mol Biomarkers. 2018;22(9):526–540. doi:10.1089/gtmb.2018.0110
   PubMed Web of Science ®Google Scholar
• Inoue H, Mashimo Y, Funamizu M, et al. Association study of the C3 gene with adult and childhood asthma. J Hum Genet. 2008;53(8):728–738. doi:10.1007/s10038-008-0304-0
   PubMed Web of Science ®Google Scholar
• Zhang S, Zhou N, Liu R, et al. Association between polymorphisms of the complement 3 Gene and schizophrenia in a han chinese population. Cell Physiol Biochem. 2018;46(6):2480–2486. doi:10.1159/000489654
   PubMedGoogle Scholar
• Cai G, Li L, Chen Y, et al. Complement C3 gene polymorphisms are associated with lipid levels, but not the risk of coronary artery disease, a case-control study. Lipids Health Dis. 2019;18(1):217. doi:10.1186/s12944-019-1163-8
   PubMed Web of Science ®Google Scholar
• Phillips CM, Goumidi L, Bertrais S, et al. Complement component 3 polymorphisms interact with polyunsaturated fatty acids to modulate risk of metabolic syndrome. Am J Clin Nutr. 2009;90(6):1665–1673. doi:10.3945/ajcn.2009.28101
   PubMed Web of Science ®Google Scholar
• Hu W, Li K, Han H, et al. Circulating levels of CILP2 are elevated in coronary heart disease and associated with atherosclerosis. Oxid Med Cell Longev. 2020;2020:1871984. doi:10.1155/2020/1871984
   PubMed Web of Science ®Google Scholar
• King RJ, Schuett K, Tiede C, et al. Fibrinogen interaction with complement C3, a potential therapeutic target to reduce thrombosis risk. Haematologica. 2021;106(6):1616–1623. doi:10.3324/haematol.2019.239558
   PubMed Web of Science ®Google Scholar
• King R, Tiede C, Simmons K, et al. Inhibition of complement C3 and fibrinogen interaction, a potential novel therapeutic target to reduce cardiovascular disease in diabetes. Lancet. 2015;385(Suppl 1):S57. doi:10.1016/S0140-6736(15)60372-5
   PubMedGoogle Scholar
• Nagareddy PR, Murphy AJ, Stirzaker RA, et al. Hyperglycemia promotes myelopoiesis and impairs the resolution of atherosclerosis. Cell Metab. 2013;17(5):695–708. doi:10.1016/j.cmet.2013.04.001
   PubMed Web of Science ®Google Scholar
• Lee JS, Chang PY, Zhang Y, et al. Triglyceride and HDL-C dyslipidemia and risks of coronary heart disease and ischemic stroke by glycemic dysregulation status, the strong heart study. Diabetes Care. 2017;40(4):529–537. doi:10.2337/dc16-1958
   PubMed Web of Science ®Google Scholar
• Husing A, Kabar I, Schmidt HH. Lipids in liver transplant recipients. World J Gastroenterol. 2016;22(12):3315–3324. doi:10.3748/wjg.v22.i12.3315
   PubMed Web of Science ®Google Scholar
• Zhang WJ, Su WW, Li PB, et al. Naoxintong capsule inhibits the development of cardiovascular pathological changes in bama minipig through improving gut microbiota. Front Pharmacol. 2019;10:1128. doi:10.3389/fphar.2019.01128
   PubMed Web of Science ®Google Scholar
• Chen YH, Chau LY, Chen JW, et al. Serum bilirubin and ferritin levels link heme oxygenase-1 gene promoter polymorphism and susceptibility to coronary artery disease in diabetic patients. Diabetes Care. 2008;31(8):1615–1620. doi:10.2337/dc07-2126
   PubMed Web of Science ®Google Scholar
• Hinds TD, Stec DE. Bilirubin, a cardiometabolic signaling molecule. Hypertension. 2018;72(4):788–795. doi:10.1161/HYPERTENSIONAHA.118.11130
   PubMed Web of Science ®Google Scholar
• Elizondo-Montemayor L, Ugalde-Casas PA, Lam-Franco L, et al. Association of ALT and the metabolic syndrome among Mexican children. Obes Res Clin Pract. 2014;8(1):e79–87. doi:10.1016/j.orcp.2012.08.191
   PubMed Web of Science ®Google Scholar
• Ren L, Cui Q, Liu W, et al. Novel GLP-1 analog supaglutide stimulates insulin secretion in mouse and human islet beta-cells and improves glucose homeostasis in diabetic mice. Front Physiol. 2019;10:930. doi:10.3389/fphys.2019.00930
   PubMed Web of Science ®Google Scholar
• Patti G, Cavallari I, Andreotti F, et al. Prevention of atherothrombotic events in patients with diabetes mellitus, from antithrombotic therapies to new-generation glucose-lowering drugs. Nat Rev Cardiol. 2019;16(2):113–130. doi:10.1038/s41569-018-0080-2
   PubMed Web of Science ®Google Scholar
• Hess K, Alzahrani SH, Mathai M, et al. A novel mechanism for hypofibrinolysis in diabetes, the role of complement C3. Diabetologia. 2012;55(4):1103–1113. doi:10.1007/s00125-011-2301-7
   PubMed Web of Science ®Google Scholar